John Schroer runs this relatively conservative offering, which has historically focussed on pharmaceutical stocks. However, Schroer has been taking profits in the stellar performing pharmaceutical sector and redirecting the proceeds into biotechnology stocks with good growth potential. There is lots of appeal to a fund run by a team focussing on health science, invested in relatively defensive sectors, and with a deep a strong team of analysts. The biggest risk here is government policies relating to medical care. Spectrum European Growth Europe is an interesting region right now for a few reasons.
Economic growth is moderately strong - but low enough to skirt inflation worries.
The currency appears to be stabilized and is poised to strengthen. Global perception of the region is improving. Finally, tax reform was introduced at just the right time in countries like Ireland and Germany. There are always negatives to consider but Europe appears to have more positives in its favour. As such, this fund is a great choice.